pharmaceuticals - Page 3

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

When the stock market is hitting record highs, it's important to remember that it's really a market of stocks rather than a stock market. Not all companies are created equal. ...
Read Full Story »

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

While the overall stock market has been very strong year to date, with sectors like technology outperforming, the health care sector, which encompasses everything from pharmaceuticals to biotech to medical ...
Read Full Story »

What Drove Johnson & Johnson in Q1

Johnson & Johnson (NYSE: JNJ) released its first-quarter financial results before the markets opened on Tuesday. The health care giant said that it had $2.10 in earnings per share (EPS) ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday Morning

Johnson & Johnson (NYSE: JNJ) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus estimates are $2.04 in earnings per share (EPS) and ...
Read Full Story »

Unbelievable Swings in Big Pharma Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) have announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of ...
Read Full Story »

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer Inc. (NYSE: PFE). The Phase 1/2 ...
Read Full Story »

Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck

Shares of drug giant Pfizer Inc. (NYSE: PFE) have lagged rival Merck & Co. Inc. (NYSE: PFE). The gain of 23% for Pfizer from this time a year ago is ...
Read Full Story »

Major Pharma Sees a Few Wild Swings in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer's disease after shares of Biogen Inc. (NASDAQ: BIIB) suffered handily with the announcement that it ...
Read Full Story »

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Inc. (NYSE: PFE) is getting deeper into gene therapy. The U.S. drug giant has acquired a 15% stake in Vivet Therapeutics. On top of the investment in the French ...
Read Full Story »

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Pfizer Inc. (NYSE: PFE) has announced that it has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer is looking to ...
Read Full Story »

Bad News for AbbVie and Multiple Myeloma Patients

AbbVie Inc. (NYSE: ABBV) and patients suffering from multiple myeloma have seen some additional bad news. The Food and Drug Administration (FDA) has placed a partial clinical hold on clinical ...
Read Full Story »

How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?

A California jury has awarded $29 million to a woman who claimed talcum-powder-based Johnson & Johnson (NYSE: JNJ) products caused her cancer. This ruling is the most recent defeat, out of ...
Read Full Story »